Eisai Co Ltd (ESALF) 52.5000 $ESALF
FDA clears Eisai drug for thyroid cancer
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:02AM CST
Anticancer Agent Lenvatinib Phase III Trial Results Published In New England Journal of Medicine
JCN Newswire - Thu Feb 12, 2:01AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the results from the Phase III SELECT trial of lenvatinib mesylate (lenvatinib), a novel investigative anticancer agent for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), were published in the New England Journal of Medicine (NEJM) on February 12, 2015. This marks the first time that a journal article on a Phase III trial of a systemic therapy in thyroid cancer has been published in the NEJM.
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Notice Regarding Eisai's Options Relating To Biogen Idec's Investigational Anti-Alzheimer's Disease Treatments
JCN Newswire - Wed Feb 04, 10:21PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today further details of the options that it has as part of the agreement to jointly develop and commercialize its investigational next generation Alzheimer's disease (AD) treatment candidates E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A Beta) protofibril antibody, with Biogen Idec (Headquarters: Massachusetts, the United States, CEO: George A. Scangos), which was initially announced on March 5, 2014 ("Collaboration Agreement" . This notice is made to coincide with the annual report (10-K) publicly disclosed by Biogen Idec on February 4 (EST).
BIIB: 391.66 (-0.45)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint
JCN Newswire - Sun Feb 01, 6:37PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint.
Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines
JCN Newswire - Mon Jan 26, 1:55AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" and Ajinomoto Pharmaceuticals Co., Ltd. (Headquarters: Tokyo, President: Takashi Nagamachi, "Ajinomoto Pharmaceuticals" announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines.
Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year
JCN Newswire - Fri Jan 23, 3:53AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's third inclusion on the list in as many years, and Eisai is the only company from Japan to be included in 2015.
Rhabdomyosarcoma Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Sat Jan 03, 11:00AM CST
The report "Rhabdomyosarcoma Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma is a cancerous tumor of the muscles that are attached to the bones. It mostly occurs in areas naturally lacking in skeletal muscle such as the head and neck, the urogenital tract, and the arms or legs. The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. The most common symptom is a mass that may or may not be painful and other symptoms vary depending on location of the tumor. Complete Report is Available @ http://www.reportsnreports.com/reports/321892...-2014.html .
BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Aspergillosis - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/tnt27n/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Aspergillosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Eisai Co., Ltd. - F2G Ltd - MABLife S.A.S - Merck & Co., Inc. - Novabiotics Ltd - Sealife PHARMA GMBH - Sigma-Tau S.p.A. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/tn...ergillosis
MRK: 58.81 (-0.07)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment
JCN Newswire - Wed Dec 17, 3:25AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment.
Lewy body Dementia - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/6wc3pm/lewy_body) has announced the addition of the "Lewy body Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lewy body Dementia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Eisai Co., Ltd. - ProteoTech, Inc. - BioArctic Neuroscience AB - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/6wc3pm/lewy_body
Menopausal Hot Flashes - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/tnl34l/menopausal_hot) has announced the addition of the "Menopausal Hot Flashes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Menopausal Hot Flashes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Menopausal Hot Flashes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Menopausal Hot Flashes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Eisai Co., Ltd. - Pherin Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/tn...pausal_hot
AMGN: 153.48 (+0.30)
Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 58.81 (-0.07), PBS.VN: 0.040 (-0.005), NVS: 102.20 (-0.17)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia
JCN Newswire - Wed Dec 10, 2:47AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. In the study, E2006 demonstrated a statistically significant improvement in sleep initiation and sleep maintenance without increasing next-day residual sleepiness when compared with placebo.
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
FDA clears Eisai drug for thyroid cancer
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 10:02AM CST
Anticancer Agent Lenvatinib Phase III Trial Results Published In New England Journal of Medicine
JCN Newswire - Thu Feb 12, 2:01AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the results from the Phase III SELECT trial of lenvatinib mesylate (lenvatinib), a novel investigative anticancer agent for patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), were published in the New England Journal of Medicine (NEJM) on February 12, 2015. This marks the first time that a journal article on a Phase III trial of a systemic therapy in thyroid cancer has been published in the NEJM. Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Notice Regarding Eisai's Options Relating To Biogen Idec's Investigational Anti-Alzheimer's Disease Treatments
JCN Newswire - Wed Feb 04, 10:21PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today further details of the options that it has as part of the agreement to jointly develop and commercialize its investigational next generation Alzheimer's disease (AD) treatment candidates E2609, a BACE inhibitor, and BAN2401, an anti-amyloid beta (A Beta) protofibril antibody, with Biogen Idec (Headquarters: Massachusetts, the United States, CEO: George A. Scangos), which was initially announced on March 5, 2014 ("Collaboration Agreement" . This notice is made to coincide with the annual report (10-K) publicly disclosed by Biogen Idec on February 4 (EST). BIIB: 391.66 (-0.45)
Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75+ Companies Operating in this Market
M2 - Mon Feb 02, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/jkszvl/biomarker) has announced the addition of the "Global Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report Featuring 75 Companies Operating in this Market" report to their offering. Biomarker Technology Platforms for Cancer Diagnoses and Therapies Report particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor's offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer. The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. Key Topics Covered: 1. Overview 2. Introduction to Cancer Biology and the Diagnostic Industry 3. Market Analysis of the Cancer Biomarkers Space 4. Major Clinical Applications of Cancer Biomarkers 5. Breast Cancer 6. Ovarian Cancer 7. Prostate Cancer 8. Bladder Cancer 9. Colorectal Cancer 10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing 11. Leukemia Biomarkers 12. Lung Cancer 13. Enabling Technologies for Oncology Biomarker Discovery 14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics 15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends 16. Business Trends in the Industry 17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms Companies Mentioned: Click below to view full list of companies - Abbott Diagnostics - Affymetrix, Inc. - Agendia BV - Agensys, Inc. (Astellas Pharma US) - Agilent Technologies - Beckman Coulter, Inc. - Biocode Hycel S.A. - BioCurex, Inc. - Biomarker Technologies, LLC - Biomedical Diagnostics, LLC - Biomerica, Inc. - bioM?rieux - Cangen Biotechnologies, Inc. - DRG International, Inc. - EDP Biotech Corporation - Eisai Co., Ltd. - Eli Lilly & Co. - Immunomedics, Inc. - Incyte Pharmaceuticals, Inc. - InterGenetics, Inc. - Ipsogen (Qiagen Marseille) - Mitsubishi Kagaku Medical - MolecularMD - Myriad Genetics, Inc. - Oncothyreon, Inc. (Formerly known as Biomira) - OPKO Health, Inc. - Roche Molecular Diagnostics - SensiGen, LLC (Sequenom Center for Molecular Medicine) - Siemens Healthcare Diagnostics, Inc. - Vermillion, Inc. (Formerly Ciphergen) For more information visit http://www.researchandmarkets.com/research/jkszvl/biomarker
MYGN: 34.03 (+0.40), IMMU: 3.84 (unch), A: 40.15 (+0.13), INCY: 75.94 (+0.28), LLY: 70.56 (+0.03), ONTY: 1.57 (unch), VRML: 2.08 (+0.12), AFFX: 11.45 (+0.02), SQNM: 3.62 (unch), OPK: 13.80 (-0.28)
Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint
JCN Newswire - Sun Feb 01, 6:37PM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that the Phase II part of a Phase I/II clinical trial (Study 205) of its in-house developed anticancer agent lenvatinib mesylate (lenvatinib) in unresectable advanced or metastatic renal cell carcinoma has met its primary endpoint. Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines
JCN Newswire - Mon Jan 26, 1:55AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
and Ajinomoto Pharmaceuticals Co., Ltd. (Headquarters: Tokyo, President: Takashi Nagamachi, "Ajinomoto Pharmaceuticals" announced today that LIVAMIN Oral Granules (granules of isoleucine, leucine and valine, brand name in Japan: LIVACT Granules), a branched-chain amino acid formula, was launched in the Philippines. Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year
JCN Newswire - Fri Jan 23, 3:53AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has been listed in the 2015 Global 100 Most Sustainable Corporations in the World (Global 100) Index, a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's third inclusion on the list in as many years, and Eisai is the only company from Japan to be included in 2015. Rhabdomyosarcoma Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Sat Jan 03, 11:00AM CST
The report "Rhabdomyosarcoma Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rhabdomyosarcoma. Rhabdomyosarcoma is a cancerous tumor of the muscles that are attached to the bones. It mostly occurs in areas naturally lacking in skeletal muscle such as the head and neck, the urogenital tract, and the arms or legs. The cause of rhabdomyosarcoma is unknown. It is a rare tumor with only several hundred new cases per year in the United States. The most common symptom is a mass that may or may not be painful and other symptoms vary depending on location of the tumor. Complete Report is Available @ http://www.reportsnreports.com/reports/321892...-2014.html .
BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Aspergillosis - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/tnt27n/aspergillosis) has announced the addition of the "Aspergillosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Aspergillosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Aspergillosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Aspergillosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Astellas Pharma Inc. - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Eisai Co., Ltd. - F2G Ltd - MABLife S.A.S - Merck & Co., Inc. - Novabiotics Ltd - Sealife PHARMA GMBH - Sigma-Tau S.p.A. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/tn...ergillosis
MRK: 58.81 (-0.07)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment
JCN Newswire - Wed Dec 17, 3:25AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has been listed for the 13th consecutive year since 2002 in the FTSE4Good Index Series, a global index for socially responsible investment. Lewy body Dementia - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/6wc3pm/lewy_body) has announced the addition of the "Lewy body Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lewy body Dementia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Eisai Co., Ltd. - ProteoTech, Inc. - BioArctic Neuroscience AB - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/6wc3pm/lewy_body
Menopausal Hot Flashes - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/tnl34l/menopausal_hot) has announced the addition of the "Menopausal Hot Flashes - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Menopausal Hot Flashes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Menopausal Hot Flashes and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Menopausal Hot Flashes - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Menopausal Hot Flashes pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Eisai Co., Ltd. - Pherin Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/tn...pausal_hot
AMGN: 153.48 (+0.30)
Candidiasis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9jx8b8/candidiasis) has announced the addition of the "Candidiasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aureogen Biosciences, Inc. - Basilea Pharmaceutica AG - Biomar Microbial Technologies - Cellceutix Corporation - Eisai Co., Ltd. - Merck & Co., Inc. - NovaDigm Therapeutics, Inc. - Novabiotics Ltd - Novartis AG - Pacgen Life Science Corporation - Panacela Labs, Inc. - Sealife PHARMA GMBH - Sequella, Inc. - iCo Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/9j...andidiasis
MRK: 58.81 (-0.07), PBS.VN: 0.040 (-0.005), NVS: 102.20 (-0.17)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rd5zp/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - AB Science - Aestus Therapeutics - AlzProtect - Amorfix Life Sciences - Anavex Life Sciences - Angion Biomedica - Apodemus - BBB Therapeutics - BioCrea - Biogen Idec - Bionure Farma - BrainStorm Cell Therapeutics - CalAsia Pharmaceuticals - Calico - Cellceutix - Cellular Biomedicine Group - Chronos Therapeutics Limited - Cytokinetics - D-Pharm - Daval International Ltd. - Eisai Co., Ltd. - Evotec AG - ExSAR Corporation - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - Glialogix, Inc. - Grifols, S.A. - Herantis Pharma plc. - ImStar Therapeutics Inc. - Jeil Pharmaceutical Co., Ltd. - Kadimastem Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lead Discovery Center GmbH - Maas Biolab - Mallinckrodt plc - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Holding AG - Neurodyn Inc. - Neurotec Pharma SL - Neurotune AG - Newron Pharmaceuticals S.p.A. - Nexgenix Pharmaceuticals, LLC - Orphazyme ApS - Paladin Labs Inc. - Pharnext SAS - Q Therapeutics, Inc. - Regenesance BV - reMYND - RhinoCyte, Inc. - RXi Pharmaceuticals Corporation - Saneron CCEL Therapeutics, Inc. - SK Biopharmaceuticals Co., Ltd. - Spherium biomed S.L. - Varinel, Inc. - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/9r...myotrophic
BIIB: 391.66 (-0.45), KNMD: (), GSK: 47.94 (+1.99), BCLI: 3.86 (-0.02), CBMG: 24.32 (-1.17), CUR: 3.41 (+0.13)
Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia
JCN Newswire - Wed Dec 10, 2:47AM CST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has presented data from a Phase II clinical study (Study 201) on its in-house-developed investigational dual orexin receptor antagonist (DORA) E2006 in patients with insomnia disorder at the 53rd American College of Neuropsychopharmacology (ACNP) Annual Meeting held from December 7 through 11, 2014, in Phoenix, Arizona in the United States. In the study, E2006 demonstrated a statistically significant improvement in sleep initiation and sleep maintenance without increasing next-day residual sleepiness when compared with placebo. RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
